Melita Irving | Group Leader at the Ludwig Institute for Cancer Research
University of Lausanne

Originally from Canada, Dr. Melita Irving began working in the field of T-cell engineering for cancer immunotherapy in Switzerland in 2007. She has been a group leader at the Ludwig Institute for Cancer Research in the Department of Oncology at the University of Lausanne for the past 12 years. Dr. Irving’s research is focused on the optimization of viral and non-viral gene-engineering tools, and the development of function and safety-enhanced next-generation CAR- and TCR-T cells.